검색어: hybridization (영어 - 몰타어)

the method used for identification (colony, hybridization, immuno-blot, etc.);
il-metodu wżat għall-identifikazzjoni (kolonja, ibridizzazzjoni, immuno-blot, eċċ.);

a minority of patients were tested using fluorescence in-situ hybridization (fish).
minoranza ta’ pazjenti kienu ittestjati bl- użu ta’ fluorescence in-situ hybridization (fish).

cell fusion or hybridization techniques where live cells with new combinations of heritable genetic material are formed through the fusion of two or more cells by means of methods that do not occur naturally.
fużjoni ta' ċelloli jew tekniċi ta' ibridiżmu fejn ċelloli ħajjin b'kombinazzjonijiet ġodda ta' materjal ġenetiku illi jintiret huma fformati permezz ta' għaqda ta' żewġ ċelloli jew aktar permezz ta' metodi illi ma jseħħux b'mod naturali.

experience in patients with hbeag positive chb and compensated liver disease: in controlled studies, 1 year of lamivudine therapy significantly suppressed hbv dna replication (34-57% of patients were below the assay detection limits (abbott genostics solution hybridization assay, llod < 1.6pg/ ml)], normalised alt level (40-72% of patients), induced hbeag seroconversion (hbeag loss and hbeab detection with hbv dna loss [by conventional assay], 16-18% of patients), improved histology (38-52% of patients had a ≥ 2 point decrease in the knodell histologic activity index [hai]) and reduced progression of fibrosis (in 3-17% of patients) and progression to cirrhosis.
esperjenza f’ pazjenti b’ chb pożittiv għall- hbeag u mard kumpensat tal- fwied: fi studji kontrollati ta 'pazjenti pożittivi għall- hbeag, sena waħda ta' terapija b ’ lamivudine żammet sostanzjalment ir - replikazzjoni ta 'dna tal- hbv {34- 57% ta' pazjenti, kellhom livelli taħt il- limiti li jitkejlu fl- assay (soluzzjoni abbott genostics hybridization assay, llod < 1. 6pg/ ml)}, ġiebet għan- normal il- livell ta 'alt (40- 72% ta' pazjenti), ikkaġunat serokonverżjoni tal- hbeag (telf ta 'dna tal- hbeag u skoperta ta' hbeab b’ telf ta ’ hbv dna [b’ assay konvenzjonali], 16- 18% ta 'pazjenti), tejjbet l- istoloġija (38 - 52% ta' pazjenti kellhom tnaqqis ta ’ ≥ 2 punti fil- knodell histologic activity index [hai]) u naqqset l- avanz ta 'fibrożi (f’ 3- 17% ta ’ pazjenti u l- avanz għaċ- ċirrożi.